CPEB1
gene geneOn this page
Also known as FLJ13203CPEB
Summary
CPEB1 (cytoplasmic polyadenylation element binding protein 1, HGNC:21744) is a protein-coding gene on chromosome 15q25.2, encoding Cytoplasmic polyadenylation element-binding protein 1 (Q9BZB8). Sequence-specific RNA-binding protein that regulates mRNA cytoplasmic polyadenylation and translation initiation during oocyte maturation, early development and at postsynapse sites of neurons.
This gene encodes a member of the cytoplasmic polyadenylation element binding protein family. This highly conserved protein binds to a specific RNA sequence, called the cytoplasmic polyadenylation element, found in the 3’ untranslated region of some mRNAs. The encoded protein functions in both the cytoplasm and the nucleus. It is involved in the regulation of mRNA translation, as well as processing of the 3’ untranslated region, and may play a role in cell proliferation and tumorigenesis. Alternative splicing results in multiple transcript variants.
Source: NCBI Gene 64506 — RefSeq curated summary.
At a glance
- GWAS associations: 9
- Clinical variants (ClinVar): 71 total
- Regional missense constraint (gnomAD): 2 of 6 regions constrained (≈5% of expected missense variation)
- GTEx eGene: eQTL in 30 tissues, sQTL in 5 (q < 0.05)
- Constraint (gnomAD): pLI 1.00 (loss-of-function intolerant), LOEUF 0.18 (highly constrained)
- MANE Select transcript:
NM_001365242 - Notable: 71 clinical variants but no curated precision-oncology (CIViC) evidence yet
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:21744 |
| Approved symbol | CPEB1 |
| Name | cytoplasmic polyadenylation element binding protein 1 |
| Location | 15q25.2 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | FLJ13203, CPEB |
| Ensembl gene | ENSG00000214575 |
| Ensembl biotype | protein_coding |
| OMIM | 607342 |
| Entrez | 64506 |
Gene structure
Transcript identifiers
Ensembl transcripts: 25 — 20 protein_coding, 2 protein_coding_CDS_not_defined, 2 retained_intron, 1 nonsense_mediated_decay
MANE Select: ENST00000684509
Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 4, TSL 2: 6, TSL 3: 2, TSL 4: 3, TSL 5: 3
ENST00000684509, ENST00000563519, ENST00000566716, ENST00000567678, ENST00000568994, ENST00000569257, ENST00000570205, ENST00000611031, ENST00000611163, ENST00000614918, ENST00000614977, ENST00000615198, ENST00000616959, ENST00000617462, ENST00000617522, ENST00000617958, ENST00000618449, ENST00000618698, ENST00000620182, ENST00000902789, ENST00000902790, ENST00000902791, ENST00000902792, ENST00001009771, ENST00001009772
RefSeq mRNA: 35 — MANE Select: NM_001365242
NM_001079533, NM_001079534, NM_001079535, NM_001288819, NM_001288820, NM_001365240, NM_001365241, NM_001365242, NM_001365243, NM_001365244, NM_001365245, NM_001365246, NM_001365247, NM_001365248, NM_001365249, NM_001365250, NM_001387061, NM_001387062, NM_001387063, NM_001387064, NM_001387065, NM_001387066, NM_001387067, NM_001387068, NM_001387069, NM_001387070, NM_001387071, NM_001387072, NM_001387073, NM_001387074, NM_001387075, NM_001387076, NM_001387077, NM_001387078, NM_030594
CCDS: CCDS42072, CCDS45329, CCDS45330, CCDS92050
Canonical transcript exons
ENST00000632305 — 0 exons
Expression profiles
Bgee: expression breadth ubiquitous, 132 present calls, max score 94.40.
FANTOM5 (CAGE): breadth broad, TPM avg 3.3180 / max 60.0314, expressed in 868 samples.
Highest expression (Bgee): male germ line stem cell (sensu Vertebrata) in testis, C1 segment of cervical spinal cord, pituitary gland, adenohypophysis, Brodmann (1909) area 9.
Genetic regulation across tissues (GTEx eQTL / sQTL)
CPEB1 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 30 tissues and its splicing (sQTL) in 5 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.
showing 20 of 35 significant tissue × QTL associations:
| Tissue | QTL | q-value | Slope | Lead variant |
|---|---|---|---|---|
| Thyroid | eqtl | 2.0e-16 | +0.31 | 15:82720688:A:G |
| Esophagus Muscularis | eqtl | 1.0e-15 | +0.26 | 15:82737476:T:C |
| Esophagus Gastroesophageal Junction | eqtl | 1.2e-13 | -0.26 | 15:82396424:C:G |
| Nerve Tibial | eqtl | 1.2e-12 | +0.19 | 15:82720688:A:G |
| Muscle Skeletal | eqtl | 3.7e-12 | +0.36 | 15:82734974:C:T |
| Brain Cerebellum | sqtl | 3.2e-11 | +0.86 | 15:82697158:C:T |
| Artery Tibial | eqtl | 1.1e-10 | -0.18 | 15:82438114:A:AGTTTTT |
| Colon Transverse | eqtl | 1.2e-10 | +0.17 | 15:82720688:A:G |
| Artery Aorta | eqtl | 2.8e-08 | -0.24 | 15:82417894:T:G |
| Adipose Subcutaneous | eqtl | 1.3e-07 | -0.14 | 15:82627794:A:T |
| Esophagus Mucosa | eqtl | 2.5e-07 | +0.17 | 15:82716625:A:G |
| Colon Sigmoid | eqtl | 1.2e-06 | +0.23 | 15:82133829:G:C |
| Adipose Visceral Omentum | eqtl | 2.4e-06 | +0.19 | 15:82702814:A:G |
| Cells Cultured fibroblasts | eqtl | 2.2e-04 | +0.12 | 15:82690920:T:TGCTGGGATTACAGGCATGAGCCAC |
| Breast Mammary Tissue | eqtl | 2.3e-04 | +0.16 | 15:82674020:A:G |
| Brain Frontal Cortex BA9 | eqtl | 5.7e-04 | -0.19 | 15:82621387:C:T |
| Brain Cortex | sqtl | 6.8e-04 | -0.58 | 15:82630710:C:T |
| Brain Frontal Cortex BA9 | sqtl | 2.7e-03 | -0.59 | 15:82571543:A:C |
| Testis | eqtl | 3.9e-03 | -0.09 | 15:82195898:A:T |
| Brain Hippocampus | eqtl | 5.4e-03 | -0.18 | 15:82214561:G:T |
FANTOM5 promoters
showing 10 of 11 alternative TSS:
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 151251 | 0.9726 | 466 |
| 151248 | 0.8639 | 370 |
| 151255 | 0.5796 | 202 |
| 151249 | 0.2288 | 131 |
| 151256 | 0.2091 | 98 |
| 151250 | 0.1671 | 90 |
| 151258 | 0.1047 | 46 |
| 151259 | 0.0820 | 41 |
| 151257 | 0.0609 | 28 |
| 151253 | 0.0316 | 17 |
Top tissues by expression
showing 100 of 134 tissues by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 94.40 | gold quality |
| C1 segment of cervical spinal cord | UBERON:0006469 | 93.08 | gold quality |
| pituitary gland | UBERON:0000007 | 90.87 | gold quality |
| adenohypophysis | UBERON:0002196 | 90.82 | gold quality |
| Brodmann (1909) area 9 | UBERON:0013540 | 90.24 | gold quality |
| testis | UBERON:0000473 | 90.16 | gold quality |
| right testis | UBERON:0004534 | 89.98 | gold quality |
| corpus callosum | UBERON:0002336 | 89.94 | gold quality |
| superior frontal gyrus | UBERON:0002661 | 89.57 | gold quality |
| left testis | UBERON:0004533 | 89.30 | gold quality |
| substantia nigra | UBERON:0002038 | 89.22 | gold quality |
| hypothalamus | UBERON:0001898 | 89.17 | gold quality |
| prefrontal cortex | UBERON:0000451 | 88.85 | gold quality |
| frontal cortex | UBERON:0001870 | 88.67 | gold quality |
| dorsolateral prefrontal cortex | UBERON:0009834 | 88.37 | gold quality |
| right frontal lobe | UBERON:0002810 | 88.30 | gold quality |
| right hemisphere of cerebellum | UBERON:0014890 | 88.30 | gold quality |
| primary visual cortex | UBERON:0002436 | 88.26 | gold quality |
| cerebellar hemisphere | UBERON:0002245 | 87.95 | gold quality |
| cerebellar cortex | UBERON:0002129 | 87.90 | gold quality |
| cerebellum | UBERON:0002037 | 87.86 | gold quality |
| cerebral cortex | UBERON:0000956 | 87.62 | gold quality |
| Ammon’s horn | UBERON:0001954 | 87.62 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 86.87 | gold quality |
| anterior cingulate cortex | UBERON:0009835 | 86.65 | gold quality |
| brain | UBERON:0000955 | 86.64 | gold quality |
| temporal lobe | UBERON:0001871 | 83.88 | gold quality |
| amygdala | UBERON:0001876 | 83.82 | gold quality |
| nucleus accumbens | UBERON:0001882 | 83.29 | gold quality |
| putamen | UBERON:0001874 | 83.05 | gold quality |
| caudate nucleus | UBERON:0001873 | 82.63 | gold quality |
| tibial nerve | UBERON:0001323 | 82.14 | gold quality |
| mucosa of stomach | UBERON:0001199 | 81.84 | gold quality |
| right uterine tube | UBERON:0001302 | 81.52 | gold quality |
| endocervix | UBERON:0000458 | 80.75 | gold quality |
| right ovary | UBERON:0002118 | 79.26 | gold quality |
| urinary bladder | UBERON:0001255 | 78.89 | gold quality |
| ovary | UBERON:0000992 | 78.82 | gold quality |
| left ovary | UBERON:0002119 | 78.75 | gold quality |
| uterine cervix | UBERON:0000002 | 77.98 | gold quality |
| muscle layer of sigmoid colon | UBERON:0035805 | 77.97 | gold quality |
| ectocervix | UBERON:0012249 | 77.92 | gold quality |
| fallopian tube | UBERON:0003889 | 77.90 | gold quality |
| islet of Langerhans | UBERON:0000006 | 77.08 | gold quality |
| calcaneal tendon | UBERON:0003701 | 76.78 | gold quality |
| esophagogastric junction muscularis propria | UBERON:0035841 | 76.52 | gold quality |
| stromal cell of endometrium | CL:0002255 | 76.30 | gold quality |
| body of uterus | UBERON:0009853 | 76.07 | gold quality |
| smooth muscle tissue | UBERON:0001135 | 75.81 | gold quality |
| vagina | UBERON:0000996 | 75.70 | gold quality |
| right adrenal gland | UBERON:0001233 | 75.46 | gold quality |
| gall bladder | UBERON:0002110 | 75.37 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 75.37 | gold quality |
| lower esophagus muscularis layer | UBERON:0035833 | 74.64 | gold quality |
| lower esophagus | UBERON:0013473 | 74.59 | gold quality |
| left adrenal gland | UBERON:0001234 | 74.04 | gold quality |
| popliteal artery | UBERON:0002250 | 73.88 | gold quality |
| tibial artery | UBERON:0007610 | 73.85 | gold quality |
| left adrenal gland cortex | UBERON:0035825 | 73.69 | gold quality |
| sural nerve | UBERON:0015488 | 73.53 | gold quality |
| fundus of stomach | UBERON:0001160 | 73.39 | gold quality |
| right coronary artery | UBERON:0001625 | 73.27 | gold quality |
| left uterine tube | UBERON:0001303 | 73.08 | gold quality |
| adrenal gland | UBERON:0002369 | 73.06 | gold quality |
| hindlimb stylopod muscle | UBERON:0004252 | 72.67 | gold quality |
| descending thoracic aorta | UBERON:0002345 | 72.66 | gold quality |
| myometrium | UBERON:0001296 | 72.62 | gold quality |
| ascending aorta | UBERON:0001496 | 72.54 | gold quality |
| thoracic aorta | UBERON:0001515 | 72.54 | gold quality |
| multicellular organism | UBERON:0000468 | 72.17 | gold quality |
| colon | UBERON:0001155 | 71.94 | gold quality |
| endometrium | UBERON:0001295 | 71.32 | gold quality |
| rectum | UBERON:0001052 | 70.90 | gold quality |
| muscle tissue | UBERON:0002385 | 70.47 | gold quality |
| left coronary artery | UBERON:0001626 | 70.37 | gold quality |
| gastrocnemius | UBERON:0001388 | 70.28 | gold quality |
| intestine | UBERON:0000160 | 70.15 | gold quality |
| omental fat pad | UBERON:0010414 | 70.10 | gold quality |
| right atrium auricular region | UBERON:0006631 | 70.06 | gold quality |
| adipose tissue | UBERON:0001013 | 70.05 | gold quality |
| subcutaneous adipose tissue | UBERON:0002190 | 70.02 | gold quality |
| muscle of leg | UBERON:0001383 | 69.97 | gold quality |
| thoracic mammary gland | UBERON:0005200 | 69.15 | gold quality |
| skeletal muscle tissue | UBERON:0001134 | 69.07 | gold quality |
| esophagus | UBERON:0001043 | 68.79 | gold quality |
| transverse colon | UBERON:0001157 | 68.46 | gold quality |
| pancreas | UBERON:0001264 | 67.85 | gold quality |
| skin of leg | UBERON:0001511 | 66.81 | gold quality |
| prostate gland | UBERON:0002367 | 66.74 | gold quality |
| small intestine | UBERON:0002108 | 66.56 | gold quality |
| thyroid gland | UBERON:0002046 | 66.48 | gold quality |
| body of stomach | UBERON:0001161 | 66.46 | gold quality |
| small intestine Peyer’s patch | UBERON:0003454 | 66.32 | gold quality |
| apex of heart | UBERON:0002098 | 66.31 | gold quality |
| stomach | UBERON:0000945 | 66.23 | gold quality |
| vermiform appendix | UBERON:0001154 | 66.14 | gold quality |
| zone of skin | UBERON:0000014 | 65.93 | gold quality |
| left lobe of thyroid gland | UBERON:0001120 | 65.79 | gold quality |
| cortex of kidney | UBERON:0001225 | 65.74 | gold quality |
| right lobe of thyroid gland | UBERON:0001119 | 65.64 | gold quality |
Single-cell (SCXA)
Detected in 2 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | no | 2.03 |
| E-MTAB-6379 | no | 0.40 |
HPA expression
RNA tissue specificity: Tissue enhanced
showing 60 of 76 HPA tissues / cells by nTPM:
| Tissue / cell | Axis | nTPM |
|---|---|---|
| Locus coeruleus | tissue | 68.4 |
| Postcentral gyrus | tissue | 42.3 |
| Spinal cord | tissue | 40.9 |
| Hippocampus | tissue | 37.9 |
| Hippocampal formation | tissue | 30.7 |
| Testis | tissue | 30.4 |
| Medulla oblongata | tissue | 30.3 |
| Pons | tissue | 28.8 |
| Nucleus accumbens | tissue | 28.6 |
| Substantia nigra | tissue | 27.3 |
| Choroid plexus | tissue | 26.4 |
| Midbrain | tissue | 24.4 |
| Hypothalamus | tissue | 23.0 |
| Prefrontal cortex | tissue | 22.9 |
| Cerebral cortex | tissue | 22.9 |
| Motor cortex | tissue | 22.8 |
| Corpus callosum | tissue | 22.8 |
| Thalamus | tissue | 22.7 |
| Somatosensory cortex | tissue | 22.7 |
| Frontal cortex | tissue | 22.5 |
| Retrosplenial and cingulate cortex | tissue | 21.9 |
| Insular cortex | tissue | 20.7 |
| Occipital cortex | tissue | 20.6 |
| Superior colliculi | tissue | 20.4 |
| Retrosplenial cortex | tissue | 20.1 |
| Temporal cortex | tissue | 20.1 |
| Periaqueductal gray | tissue | 19.9 |
| Pituitary gland | tissue | 19.4 |
| Entorhinal cortex | tissue | 18.7 |
| Olfactory bulb | tissue | 18.2 |
| Amygdala | tissue | 17.2 |
| Septum | tissue | 16.6 |
| Ventral forebrain | tissue | 16.0 |
| Cerebellum | tissue | 14.7 |
| Putamen | tissue | 11.5 |
| Basal ganglia | tissue | 10.8 |
| Caudate putamen | tissue | 10.6 |
| Tongue | tissue | 9.8 |
| Ovary | tissue | 8.8 |
| Fallopian tube | tissue | 7.8 |
| Epididymis | tissue | 7.4 |
| Vagina | tissue | 5.5 |
| Retina | tissue | 4.9 |
| Adrenal gland | tissue | 4.7 |
| Cervix | tissue | 4.2 |
| Gallbladder | tissue | 3.7 |
| Endometrium 1 | tissue | 3.6 |
| Seminal vesicle | tissue | 3.5 |
| Urinary bladder | tissue | 3.4 |
| Esophagus | tissue | 3.3 |
| Smooth muscle | tissue | 3.2 |
| Heart muscle | tissue | 2.7 |
| Skeletal muscle | tissue | 2.4 |
| Rectum | tissue | 2.3 |
| Thyroid gland | tissue | 2.2 |
| Prostate | tissue | 2.2 |
| Colon | tissue | 1.9 |
| Breast | tissue | 1.6 |
| Adipose tissue | tissue | 1.6 |
| Pancreas | tissue | 1.6 |
Brain sub-regions (HPA Brain Atlas): detected in 189; highest nTPM — Parieto-temporal junction (white matter) (83.6), Dorsal funiculus (white matter) (74.9), Corpus callosum, splenium (white matter) (69.1), Temporal white matter (66.0), Cerebellar white matter (65.7).
Regulation
Is transcription factor: no
Upstream regulators (CollecTRI, top): EED, EZH2
miRNA regulators (miRDB)
Targeting CPEB1 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).
showing 30 of 164 miRNAs:
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-12118 | 100.00 | 65.88 | 1270 |
| HSA-MIR-3646 | 100.00 | 73.56 | 5283 |
| HSA-MIR-3613-3P | 100.00 | 76.36 | 7965 |
| HSA-MIR-5692A | 100.00 | 74.40 | 6850 |
| HSA-MIR-4500 | 99.99 | 72.72 | 2367 |
| HSA-MIR-6759-5P | 99.99 | 66.54 | 785 |
| HSA-MIR-548AW | 99.99 | 72.57 | 3559 |
| HSA-LET-7A-5P | 99.98 | 72.29 | 1790 |
| HSA-LET-7B-5P | 99.98 | 72.31 | 1790 |
| HSA-LET-7C-5P | 99.98 | 72.29 | 1790 |
| HSA-LET-7E-5P | 99.98 | 72.29 | 1790 |
| HSA-LET-7F-5P | 99.98 | 72.56 | 1784 |
| HSA-LET-7G-5P | 99.98 | 72.37 | 1784 |
| HSA-LET-7I-5P | 99.98 | 72.37 | 1788 |
| HSA-MIR-98-5P | 99.98 | 72.33 | 1787 |
| HSA-MIR-12136 | 99.98 | 72.81 | 5713 |
| HSA-MIR-6891-5P | 99.98 | 66.53 | 1372 |
| HSA-MIR-3173-3P | 99.98 | 66.49 | 1217 |
| HSA-MIR-607 | 99.97 | 73.62 | 5593 |
| HSA-MIR-6793-5P | 99.97 | 65.95 | 758 |
| HSA-MIR-548AJ-3P | 99.96 | 73.38 | 5345 |
| HSA-MIR-548X-3P | 99.96 | 73.38 | 5345 |
| HSA-LET-7D-5P | 99.96 | 71.76 | 1632 |
| HSA-MIR-4458 | 99.96 | 71.64 | 1650 |
| HSA-MIR-302E | 99.96 | 70.74 | 2669 |
| HSA-MIR-570-3P | 99.96 | 72.41 | 4910 |
| HSA-MIR-1468-3P | 99.96 | 72.74 | 3797 |
| HSA-MIR-96-5P | 99.95 | 72.80 | 2140 |
| HSA-MIR-548J-3P | 99.94 | 72.61 | 4881 |
| HSA-MIR-548AE-3P | 99.93 | 72.66 | 4867 |
Functional genomics
gnomAD constraint: pLI 1, LOEUF 0.177, missense Z 2.68 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD
Regional missense constraint (gnomAD)
ENST00000684509 splits into 6 regions with different missense tolerance; 2 are missense-constrained (≈5% of the expected missense variation). Missense variants in a constrained region (low observed/expected) are more likely to be pathogenic. gnomAD
| Region (GRCh38) | Missense obs / exp | o/e | Constrained |
|---|---|---|---|
| 15:82,544,595–82,549,539 | 98 / 157.6 | 0.62 | no |
| 15:82,549,540–82,549,579 | 0 / 17.4 | 0.00 | yes (p 3.0e-05) |
| 15:82,549,580–82,553,947 | 99 / 161.3 | 0.61 | no |
| 15:82,553,948–82,557,778 | 128 / 129.1 | 0.99 | no |
| 15:82,557,779–82,557,824 | 3 / 18.2 | 0.16 | yes (p 3.6e-04) |
| 15:82,557,825–82,628,459 | 223 / 228.6 | 0.98 | no |
Literature-anchored findings (GeneRIF, showing 35)
- CPEB1 has a role in compartmentalization of mRNA metabolism in the cytoplasm, between dcp1 bodies and stress granules (PMID:15731006)
- Results show that CPEB1 is continuously shuttling between nucleus and cytoplasm, and its export is controlled by two redundant motifs dependent on the nuclear export receptor Crm1. (PMID:18923137)
- CPEB controls senescence and bioenergetics in human cells at least in part by modulating p53 mRNA polyadenylation-induced translation (PMID:19141477)
- U6snRNA, GAPDH mRNA and CPEB1 mRNA levels may be useful as tumor markers for genital cancers. (PMID:19161537)
- The authors show that the human CPEB1 can repress the activity of the reporter construct containing the HPV-16 early sequences. This repression can be counteracted by a human cytoplasmic poly(A) polymerase, hGLD-2 fused to CPEB1. (PMID:20144904)
- The loss of function CPEB1 protein would enhance tumorigenesis by promoting the survival of rapidly dividing and hypermetabolic tumor cells as levels of available nutrients decline. (PMID:20339377)
- Gld4, a second non-canonical poly(A) polymerase, was found to regulate p53 mRNA polyadenylation/translation in a CPEB-dependent manner (PMID:21478871)
- The first evidence of CPEB1 involvement in GC is presented, along with the molecular mechanism underlying the regulation of its expression and its potential role in invasion and angiogenesis. (PMID:22052064)
- depleted of CPEB demonstrated that this protein directly regulates the translation of PTEN and Stat3 mRNAs. Our results show that CPEB regulated translation is a key process involved in insulin signaling (PMID:22253608)
- CPEB-mediated zonal occludens-1 mRNA localization is essential for tight-junction assembly and mammary epithelial cell polarity (PMID:22334078)
- poly(A) polymerase Gld2, deadenylase PARN, and translation inhibitory factor neuroguidin (Ngd) are components of a dendritic CPEB-associated polyadenylation apparatus (PMID:22727665)
- CPEB accelerates deadenylation and decay of the c-myc mRNA by recruiting the Tob-Caf1 complex. (PMID:23178487)
- results reveal a novel function of CPEB1 in mediating alternative 3’-UTR processing, which is coordinated with regulation of mRNA translation, through its dual nuclear and cytoplasmic functions (PMID:23434754)
- The structural similarity to other ZZ domains suggests that the CPEB1-ZZ domain recruits sumoylated proteins during assembly of the ribonucleoprotein complex prior to mRNA export from the nucleus. (PMID:23500490)
- Downregulation of CPEB1 induces senescence of glioma cells in a p53-dependent manner. (PMID:23788032)
- FMRP and CPEB1, an activator of translation, are present in neuronal dendrites, are predicted to bind many of the same mRNAs and may mediate a translational homeostasis that, when imbalanced, results in fragile X syndrome. (PMID:24141422)
- Results suggest that CPEB1-mediated translational control is essential for the differentiation of GSCs. (PMID:25216517)
- CPEB1, 2, and 4, are essential to successful mitotic cell division. (PMID:26398195)
- CPEB1 regulation of MMP9 mRNA expression mediates metastasis of breast cancer cells (PMID:26411364)
- Structural Analysis of the Pin1-CPEB1 interaction and its potential role in CPEB1 degradation has been described. (PMID:26456073)
- Identify a mechanism of VEGF overexpression in liver and mesentery that promotes pathologic, but not physiologic, angiogenesis, via sequential and nonredundant functions of CPEB1 and CPEB4. (PMID:26627607)
- Expression levels of CPEB4 and CPEB1 genes are correlated with overall survival in patients with glioma. (PMID:27000226)
- WEE1 is regulated at the translational level by CPEB1 and miR-15b in a coordinated and cell-cycle-dependent manner. (PMID:27027998)
- This mechanical catalysis makes possible a positive feedback loop that would help localize the formation of CPEB fibers to active synapse areas and mark those synapses for forming a long-term memory after the prion form is established. The functional role of the CPEB helical oligomers in this mechanism carries with it implications for targeting such species in neurodegenerative diseases. (PMID:27091989)
- Upon binding to p27(Kip1) 3’UTR, CPEB1 promotes elongation of poly-A tail and the subsequent translation of p27(Kip1) mRNA. This leads to higher levels of p27(Kip1) in the cell, in turn significantly inhibiting cell proliferation, and confers to CPEB1 a potential value as a tumor suppressor in Glioblastoma. (PMID:27142352)
- The host RNA-binding protein CPEB1 was highly induced after cytomegalovirus infection and ectopic expression of CPEB1 in non-infected cells recapitulated infection-related post-transcriptional changes. CPEB1 was also required for poly(A)-tail lengthening of viral RNAs important for productive infection. (PMID:27775709)
- These findings indicated that the overexpression of miR4543p inhibited cell proliferation, migration and invasion by downregulating CPEB1. (PMID:30106109)
- study identifies CPEB1 as a potential regulator of disease progression of Posttraumatic Ankle Osteoarthritis (PMID:30411210)
- Study revealed that CPEB1 depletion might play an anti-inflammatory and antiapoptotic role in Ox-LDL-induced apoptosis and inflammation though SIRT1/LOX-1 signalling pathway. (PMID:31521690)
- CPEB1 and CPEB4 are involved in the regulation of the TAK1 and Smad signalings in human macrophages and dermal fibroblasts (PMID:32113875)
- CPEB1 deletion is not a common explanation for premature ovarian insufficiency in a Chinese cohort. (PMID:32354341)
- Estrogen promotes increased breast cancer cell proliferation and migration through downregulation of CPEB1 expression. (PMID:33162033)
- DNA hypermethylation contributes to colorectal cancer metastasis by regulating the binding of CEBPB and TFCP2 to the CPEB1 promoter. (PMID:33892791)
- CPEB alteration and aberrant transcriptome-polyadenylation lead to a treatable SLC19A3 deficiency in Huntington’s disease. (PMID:34586830)
- CPEB1 Controls NRF2 Proteostasis and Ferroptosis Susceptibility in Pancreatic Cancer. (PMID:38904009)
Cross-species orthologs
6 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | cpeb1b | ENSDARG00000008454 |
| danio_rerio | cpeb1a | ENSDARG00000045932 |
| mus_musculus | Cpeb1 | ENSMUSG00000025586 |
| rattus_norvegicus | Cpeb1 | ENSRNOG00000019161 |
| drosophila_melanogaster | orb | FBGN0004882 |
| caenorhabditis_elegans | cpb-3 | WBGENE00000772 |
Paralogs (3): CPEB3 (ENSG00000107864), CPEB4 (ENSG00000113742), CPEB2 (ENSG00000137449)
Mouse-model phenotypes
Observed phenotypes of the mouse ortholog (MGI:108442) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 13 distinct phenotype terms.
| Mouse phenotype (MP) | Records |
|---|---|
| reduced male fertility | 1 |
| female infertility | 1 |
| abnormal gametogenesis | 1 |
| abnormal reproductive system morphology | 1 |
| abnormal fertility/fecundity | 1 |
| abnormal long-term potentiation | 1 |
| oligozoospermia | 1 |
| absent ovary | 1 |
| abnormal ovary development | 1 |
| decreased testis weight | 1 |
| abnormal female meiosis | 1 |
| arrest of male meiosis | 1 |
| increased male germ cell apoptosis | 1 |
Additional cross-species homologs
Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.
| Organism | UniProt | Identity | Method |
|---|---|---|---|
| Pongo abelii | Q5R733 | 98.4% | Diamond |
| Xenopus laevis | Q52KN7 | 96.8% | Diamond |
| Carassius auratus | Q9DED5 | 95.3% | Diamond |
| Xenopus tropicalis | Q28CH2 | 86.0% | Diamond |
| Caenorhabditis remanei | Q6E3C9 | 70.6% | Diamond |
| Caenorhabditis briggsae | Q6E3D5 | 70.6% | Diamond |
| Aplysia californica | Q967R6 | 66.8% | Diamond |
| Caenorhabditis japonica | Q6E3F0 | 65.4% | Diamond |
Genomic neighbors (locus context)
Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).
| Symbol | Type | Entrez |
|---|---|---|
| CPEB1-AS1 | ncRNA | 283692 |
| RPS17 | protein-coding | 6218 |
| AP3B2 | protein-coding | 8120 |
| SNHG21 | ncRNA | 100505616 |
| FSD2 | protein-coding | 123722 |
| SCARNA15 | ncRNA | 677778 |
Protein
Protein identifiers
Cytoplasmic polyadenylation element-binding protein 1 — Q9BZB8 (reviewed: Q9BZB8)
All UniProt accessions (9): Q9BZB8, A0A024R214, A0A087WUQ9, A0A087WVR7, A0A087WXG7, A0A087X171, H3BNX1, H3BPD6, H3BTE4
UniProt curated annotations — full annotation on UniProt →
Function. Sequence-specific RNA-binding protein that regulates mRNA cytoplasmic polyadenylation and translation initiation during oocyte maturation, early development and at postsynapse sites of neurons. Binds to the cytoplasmic polyadenylation element (CPE), an uridine-rich sequence element (consensus sequence 5’-UUUUUAU-3’) within the mRNA 3’-UTR. RNA binding results in a clear conformational change analogous to the Venus fly trap mechanism. In absence of phosphorylation and in association with TACC3 is also involved as a repressor of translation of CPE-containing mRNA; a repression that is relieved by phosphorylation or degradation. Involved in the transport of CPE-containing mRNA to dendrites; those mRNAs may be transported to dendrites in a translationally dormant form and translationally activated at synapses. Its interaction with APLP1 promotes local CPE-containing mRNA polyadenylation and translation activation. Induces the assembly of stress granules in the absence of stress. Required for cell cycle progression, specifically for prophase entry.
Subunit / interactions. Interacts with kinesin, dynein, APLP1, APLP2, TENT2/GLD2 and APP. Both phosphorylated and non phosphorylated forms interact with APLP1. Interacts with TENT4B; the interaction is required for TENT4B-mediated translational control.
Subcellular location. Cytoplasm. Nucleus. P-body. Cytoplasmic granule. Synapse. Membrane. Postsynaptic density. Cell projection. Dendrite.
Tissue specificity. Isoform 1 is expressed in immature oocytes, ovary, brain and heart. Isoform 2 is expressed in brain and heart. Isoform 3 and isoform 4 are expressed in brain. Expressed in breast tumors and several tumor cell lines.
Post-translational modifications. Phosphorylated on serine/threonine residues by AURKA within positions 166 and 197. Phosphorylation and dephosphorylation on Thr-172 regulates cytoplasmic polyadenylation and translation of CPE-containing mRNAs. Phosphorylation on Thr-172 by AURKA and CAMK2A activates CPEB1. Phosphorylation on Thr-172 may be promoted by APLP1. Phosphorylation increases binding to RNA.
Domain organisation. The 2 RRM domains and the C-terminal region mediate interaction with CPE-containing RNA. The interdomain linker (411-429) acts as a hinge to fix the relative orientation of the 2 RRMs. The ZZ domain (509-566) coordinates 2 Zn ions and is probably implicated in mediating interactions with other proteins in addition to increasing the affinity of the RRMs for the CPEs. A continuous hydrophobic interface is formed between the 2 RRMs.
Similarity. Belongs to the RRM CPEB family.
Isoforms (4)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q9BZB8-1 | 1, hCPEB long, hCPEBg | yes |
| Q9BZB8-2 | 2, hCPEB short, hCPEBs | |
| Q9BZB8-3 | 3 | |
| Q9BZB8-4 | 4 |
RefSeq proteins (35): NP_001073001, NP_001073002, NP_001073003, NP_001275748, NP_001275749, NP_001352169, NP_001352170, NP_001352171, NP_001352172, NP_001352173, NP_001352174, NP_001352175, NP_001352176, NP_001352177, NP_001352178, NP_001352179, NP_001373990, NP_001373991, NP_001373992, NP_001373993, NP_001373994, NP_001373995, NP_001373996, NP_001373997, NP_001373998, NP_001373999, NP_001374000, NP_001374001, NP_001374002, NP_001374003, NP_001374004, NP_001374005, NP_001374006, NP_001374007, NP_085097 (=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR000504 | RRM_dom | Domain |
| IPR012677 | Nucleotide-bd_a/b_plait_sf | Homologous_superfamily |
| IPR032292 | CEBP1_N | Domain |
| IPR032296 | CEBP_ZZ | Domain |
| IPR034819 | CPEB | Family |
| IPR034977 | CPEB1_RRM1 | Domain |
| IPR035979 | RBD_domain_sf | Homologous_superfamily |
| IPR038446 | CEBP_ZZ_sf | Homologous_superfamily |
Pfam: PF16366, PF16367, PF16368
UniProt features (60 total): strand 20, helix 9, binding site 8, mutagenesis site 4, turn 4, splice variant 3, domain 2, modified residue 2, sequence variant 2, region of interest 2, chain 1, site 1, sequence conflict 1, compositionally biased region 1
Structure
Experimental structures (PDB)
5 structures by resolution:
| PDB | Title | Method | Resolution (Å) |
|---|---|---|---|
| 2M13 | The ZZ domain of cytoplasmic polyadenylation element binding protein 1 (CPEB1) | SOLUTION NMR | |
| 2MKE | Solution structure of CPEB1 ZZ domain in the free state | SOLUTION NMR | |
| 2MKH | Solution structure of tandem RRM domains of cytoplasmic polyadenylation element binding … | SOLUTION NMR | |
| 2MKK | Structural model of tandem RRM domains of cytoplasmic polyadenylation element binding … | SOLUTION NMR | |
| 2N1O | PIN1 WW domain in complex with a phosphorylated CPEB1 derived peptide | SOLUTION NMR |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q9BZB8-F1 | 66.05 | 0.38 |
Human Protein Atlas
Protein class: Predicted intracellular proteins
Protein evidence: Evidence at protein level
Subcellular location (HPA, imaging): cytosol; nucleoplasm
Antibody reliability (HPA): IF supported
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Catalytic / active sites (1)
| Position | Role |
|---|---|
| 411 | important for the positioning of rrm1 relative to rrm2 |
Ligand- & substrate-binding residues (8)
| Position | Role |
|---|---|
| 537 | Zn(2+) |
| 540 | Zn(2+) |
| 545 | Zn(2+) |
| 553 | Zn(2+) |
| 515 | Zn(2+) |
| 518 | Zn(2+) |
| 527 | Zn(2+) |
| 532 | Zn(2+) |
Post-translational modifications (2)
| Type | Positions |
|---|---|
| Phosphoserine | 43 |
| Phosphothreonine | 172 |
Mutagenesis-validated functional residues (4)
| Position | Phenotype |
|---|---|
| 172 | does not affect its localization. |
| 314 | abolishes stress granule assembly and correct localization in dcp1 bodies. |
| 545 | abolishes stress granule assembly and correct localization in dcp1 bodies. |
Function
Pathways and Gene Ontology
Reactome pathways
0 curated (TAS) of 0; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).
MSigDB gene sets: 248 (showing top):
GOBP_CYTOPLASMIC_TRANSLATION, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_RESPONSE_TO_ACID_CHEMICAL, GAUSSMANN_MLL_AF4_FUSION_TARGETS_G_DN, KEGG_DORSO_VENTRAL_AXIS_FORMATION, GOBP_CELLULAR_RESPONSE_TO_ACID_CHEMICAL, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, MOLENAAR_TARGETS_OF_CCND1_AND_CDK4_UP, GOBP_CELLULAR_RESPONSE_TO_INSULIN_STIMULUS, GOBP_NEGATIVE_REGULATION_OF_TRANSLATION, GOBP_TRANSLATION, GTGCCTT_MIR506, GOBP_POST_TRANSCRIPTIONAL_REGULATION_OF_GENE_EXPRESSION, AGCGCTT_MIR518F_MIR518E_MIR518A, GOMF_TRANSLATION_REGULATOR_ACTIVITY
GO Biological Process (9): mRNA processing (GO:0006397), regulation of mRNA 3’-end processing (GO:0031440), cellular response to insulin stimulus (GO:0032869), cellular response to amino acid stimulus (GO:0071230), cellular response to hypoxia (GO:0071456), negative regulation of cytoplasmic translation (GO:2000766), translation (GO:0006412), regulation of translation (GO:0006417), negative regulation of translation (GO:0017148)
GO Molecular Function (10): mRNA regulatory element binding translation repressor activity (GO:0000900), mRNA 3’-UTR binding (GO:0003730), translation factor activity, RNA binding (GO:0008135), mRNA 3’-UTR AU-rich region binding (GO:0035925), ribosome binding (GO:0043022), metal ion binding (GO:0046872), nucleic acid binding (GO:0003676), RNA binding (GO:0003723), protein binding (GO:0005515), translation regulator activity (GO:0045182)
GO Cellular Component (12): P-body (GO:0000932), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), cytosol (GO:0005829), postsynaptic density (GO:0014069), membrane (GO:0016020), dendrite (GO:0030425), neuron projection (GO:0043005), synapse (GO:0045202), ribonucleoprotein complex (GO:1990904), cytoplasmic ribonucleoprotein granule (GO:0036464)
GO top-level categories
51 GO namespaces:
| Category | Terms |
|---|---|
| cellular anatomical structure | 4 |
| translation | 3 |
| regulation of translation | 2 |
| mRNA binding | 2 |
| binding | 2 |
| cytoplasm | 2 |
| RNA processing | 1 |
| mRNA metabolic process | 1 |
| mRNA 3’-end processing | 1 |
| regulation of mRNA processing | 1 |
| response to insulin | 1 |
| cellular response to peptide hormone stimulus | 1 |
| response to amino acid | 1 |
| cellular response to acid chemical | 1 |
| response to hypoxia | 1 |
| cellular response to stress | 1 |
| cellular response to decreased oxygen levels | 1 |
| cytoplasmic translation | 1 |
| negative regulation of translation | 1 |
| regulation of cytoplasmic translation | 1 |
| peptidyltransferase activity | 1 |
| translational initiation | 1 |
| translational elongation | 1 |
| translational termination | 1 |
| macromolecule biosynthetic process | 1 |
| protein metabolic process | 1 |
| protein biosynthetic process | 1 |
| post-transcriptional regulation of gene expression | 1 |
| regulation of protein metabolic process | 1 |
| negative regulation of gene expression | 1 |
| negative regulation of protein metabolic process | 1 |
| translation repressor activity | 1 |
| RNA binding | 1 |
| translation factor activity | 1 |
| mRNA 3’-UTR binding | 1 |
| ribonucleoprotein complex binding | 1 |
| cation binding | 1 |
| nucleic acid binding | 1 |
| molecular_function | 1 |
| cytoplasmic ribonucleoprotein granule | 1 |
| intracellular membrane-bounded organelle | 1 |
| nuclear lumen | 1 |
| intracellular anatomical structure | 1 |
| asymmetric synapse | 1 |
| postsynaptic specialization | 1 |
| neuron projection | 1 |
| dendritic tree | 1 |
| plasma membrane bounded cell projection | 1 |
| cell junction | 1 |
| protein-containing complex | 1 |
| ribonucleoprotein granule | 1 |
Experimentally-supported GO annotations
GO terms backed by direct experimental evidence (ECO experimental codes) — 7 of 31 annotations. The rest are phylogenetic / computational / electronic (IEA).
7 experimentally-supported GO terms:
| GO term | NS | Evidence |
|---|---|---|
| cellular response to hypoxia | BP | direct assay |
| cellular response to insulin stimulus | BP | direct assay |
| negative regulation of cytoplasmic translation | BP | mutant phenotype |
| regulation of mRNA 3’-end processing | BP | direct assay |
| cytoplasm | CC | direct assay |
| cytosol | CC | direct assay |
| nucleoplasm | CC | direct assay |
Protein interactions and networks
STRING
showing 15 of 1,354 interactions by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| CPEB1 | NGDN | Q8NEJ9 | 923 |
| CPEB1 | TENT2 | Q6PIY7 | 805 |
| CPEB1 | EIF4E | P06730 | 772 |
| CPEB1 | AURKC | Q9UQB9 | 768 |
| CPEB1 | MSI1 | O43347 | 742 |
| CPEB1 | MOS | P00540 | 719 |
| CPEB1 | PAPOLA | P51003 | 712 |
| CPEB1 | PAPOLB | Q9NRJ5 | 712 |
| CPEB1 | PAPOLG | Q9BWT3 | 710 |
| CPEB1 | SYMPK | Q92797 | 702 |
| CPEB1 | DDX6 | P26196 | 666 |
| CPEB1 | PARN | O95453 | 631 |
| CPEB1 | FMR1 | Q06787 | 620 |
| CPEB1 | EIF4ENIF1 | Q9NRA8 | 613 |
| CPEB1 | EIF4G1 | Q04637 | 559 |
IntAct
Human interaction partners of CPEB1 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).
6 partners by confidence:
| Partner | Interaction type | MIscore | Records |
|---|---|---|---|
| CPEB4 | physical association | 0.400 | 1 |
| USP20 | physical association | 0.400 | 1 |
| SLC16A7 | physical association | 0.370 | 1 |
| APBA3 | association | 0.350 | 1 |
| CREB1 | association | 0.350 | 1 |
| CNOT1 | proximity | 0.270 | 1 |
BioGRID (180 interactions; top human partners by supporting records): SYMPK (Affinity Capture-MS; 4 records), AURKA (Affinity Capture-Western; 3 records), EIF4E (Reconstituted Complex; 3 records), APBA3 (Affinity Capture-MS; 2 records), APP (Reconstituted Complex; 2 records), CSTF2 (Affinity Capture-MS; 2 records), CSTF2T (Affinity Capture-MS; 2 records), GAN (Affinity Capture-MS; 2 records), GBP5 (Affinity Capture-MS; 2 records), HSPA4 (Proximity Label-MS; 2 records), IGF2BP1 (Proximity Label-MS; 2 records), IGF2BP2 (Proximity Label-MS; 2 records), IGF2BP3 (Proximity Label-MS; 2 records), METAP1D (Affinity Capture-MS; 2 records), MOV10 (Proximity Label-MS; 2 records)
SIGNOR signaling
1 signaling interactions:
| A | Effect | B | Mechanism |
|---|---|---|---|
| CDK1 | “up-regulates activity” | CPEB1 | phosphorylation |
Disease & clinical
Genetic variants
Variant evidence for CPEB1: 71 ClinVar records (0 pathogenic / likely pathogenic); 9 GWAS associations.
ClinVar
71 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 58 |
| Likely benign | 1 |
| Benign | 1 |
SpliceAI
Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 22 predictions of 1,895):
| Position(s) | Effect | Δscore | Sites |
|---|---|---|---|
| 15:82547141–82547142 | donor_loss | 1.0000 | 4 |
| 15:82547238–82547239 | acceptor_loss | 1.0000 | 3 |
| 15:82549458–82549459 | donor_loss | 1.0000 | 4 |
| 15:82549480 | donor_gain | 1.0000 | |
| 15:82552478–82552479 | donor_loss | 1.0000 | 5 |
| 15:82552624 | acceptor_gain | 1.0000 | |
| 15:82553997 | acceptor_gain | 1.0000 | |
| 15:82554001 | acceptor_gain | 1.0000 | |
| 15:82554006 | acceptor_gain | 1.0000 | |
| 15:82610227 | donor_gain | 1.0000 |
HPA cancer prognostics
RNA cancer specificity: Cancer enriched (Testicular Germ Cell Tumor)
Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.
1 prognostic cancer types:
| Cancer | Prognostic | p-value |
|---|---|---|
| Kidney Renal Clear Cell Carcinoma (TCGA) | unfavorable | 6.65e-06 |
Disease associations
OMIM: gene MIM:607342 | disease phenotypes:
GWAS associations
9 associations:
| Study | Trait | p-value |
|---|---|---|
| GCST011494_11 | Daytime nap | 2e-13 |
| GCST008595_96 | Cognitive ability, years of educational attainment or schizophrenia (pleiotropy) | 4e-10 |
| GCST90000047_238 | Age at first sexual intercourse | 4e-10 |
| GCST006269_315 | General cognitive ability | 3e-9 |
| GCST007201_70 | Schizophrenia | 9e-9 |
| GCST004946_174 | Schizophrenia | 3e-8 |
| GCST007201_389 | Schizophrenia | 5e-8 |
| GCST003979_7 | Excessive daytime sleepiness | 2e-7 |
| GCST007277_21 | Tourette syndrome | 7e-6 |
EFO canonical traits (from GWAS)
5 canonical traits:
| EFO ID | Trait name |
|---|---|
| EFO:0007875 | excessive daytime sleepiness measurement |
| EFO:0004337 | intelligence |
| EFO:0004784 | self reported educational attainment |
| EFO:0007828 | daytime rest measurement |
| EFO:0009749 | age at first sexual intercourse measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (CPIC guideline: no)
CTD chemical–gene interactions
26 total (human), top 26 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| bisphenol A | decreases methylation, increases expression | 4 |
| sodium arsenite | increases expression, increases abundance | 2 |
| entinostat | increases expression, affects cotreatment | 2 |
| Decitabine | affects expression | 2 |
| Cisplatin | affects expression, decreases expression | 2 |
| Valproic Acid | increases expression, increases methylation | 2 |
| methylmercuric chloride | increases expression | 1 |
| trichostatin A | increases expression | 1 |
| CGP 52608 | affects binding, increases reaction | 1 |
| 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | affects cotreatment, increases expression | 1 |
| abrine | increases expression | 1 |
| dorsomorphin | affects cotreatment, increases expression | 1 |
| Temozolomide | decreases expression | 1 |
| Sunitinib | increases expression | 1 |
| Arsenic Trioxide | increases expression | 1 |
| Air Pollutants | decreases expression, increases abundance | 1 |
| Arsenic | increases abundance, increases expression | 1 |
| Atrazine | increases expression | 1 |
| Benzo(a)pyrene | affects methylation, increases methylation | 1 |
| Rotenone | increases expression | 1 |
| Thiram | increases expression | 1 |
| Antirheumatic Agents | increases expression | 1 |
| Okadaic Acid | increases expression | 1 |
| Copper Sulfate | increases expression | 1 |
| Acrylamide | increases expression | 1 |
| Particulate Matter | decreases expression, increases abundance | 1 |
Cellosaurus cell lines
1 cell lines: 1 cancer cell line
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_F1PQ | HyCyte HeLa KO-hCPEB1 | Cancer cell line | Female |
Clinical trials (associated diseases)
Via MONDO — disease-level, not drug-specific.
1 trials:
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07164248 | Not specified | COMPLETED | Evaluation of Bone Mineral Density Indications and Outcomes in Female Adolescents: Implications for Early Detection of Osteopenia/Osteoporosis and Gynecologic Practice |
Related Atlas pages
- Disease cohort memberships (association, not causation — diseases whose associated-gene cohort lists this gene; a subset are also under Associated diseases): primary amenorrhea